CareDx Board Member Valantine Retains 38,994 Shares After Planned Sale

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

CareDx director Hannah Valantine has reported a significant insider transaction, selling 10,570 shares of common stock on June 18, 2025 at a weighted average price of $19.16 per share (ranging from $19.00 to $19.62). The total transaction value amounts to approximately $202,521.

The sale was executed under a Rule 10b5-1 trading plan established on December 12, 2024, which provides a pre-planned structure for insider trades. Following the transaction, Valantine retains direct ownership of 38,994 shares of CareDx common stock.

This transaction demonstrates a planned reduction in the director's holdings while maintaining a significant equity position in the company. The Rule 10b5-1 plan framework helps ensure compliance with insider trading regulations by establishing the trade parameters in advance.

Positive

None.

Negative

Director Hannah Valantine sold 10,570 shares worth approximately $202,000 through a pre-planned 10b5-1 trading plan at an average price of $19.16

Insider Trade Summary

Net Seller: 10,570 shares ($202,566)

Net Sell 1 txn

Insider Valantine Hannah

Role Director

Sold 10,570 shs ($203K)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,570	$19.1642	$203K

Holdings After Transaction: Common Stock — 38,994 shares (Direct)

Footnotes (1)

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the Reporting Person on December 12, 2024. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.62, inclusive. The reporting person undertakes to provide to CareDx, Inc., any security holder of CareDx, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4

Form 4 Insider Transactions: What Each Field Means →

06/23/2025 - 04:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Valantine Hannah

(Last)

(First)

(Middle)

C/O CAREDX, INC.

8000 MARINA BOULEVARD

(Street)

BRISBANE

94005

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
CareDx, Inc. [ CDNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/18/2025		S		10,570⁽¹⁾	D	$19.1642⁽²⁾	38,994	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the Reporting Person on December 12, 2024.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.62, inclusive. The reporting person undertakes to provide to CareDx, Inc., any security holder of CareDx, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4

	/s/ Hannah Valantine	06/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

How many CDNA shares did Director Hannah Valantine sell on June 18, 2025?

Director Hannah Valantine sold 10,570 shares of CareDx (CDNA) common stock on June 18, 2025.

What was the selling price of CDNA shares in Director Valantine's June 2025 transaction?

The shares were sold at a weighted average price of $19.1642, with individual transactions ranging from $19.00 to $19.62 per share.

How many CDNA shares does Hannah Valantine own after the June 2025 sale?

Following the reported transaction, Hannah Valantine directly owns 38,994 shares of CareDx (CDNA) common stock.

Was CDNA Director Valantine's stock sale part of a 10b5-1 trading plan?

Yes, the transactions were executed pursuant to a Rule 10b5-1 trading plan that was adopted by Hannah Valantine on December 12, 2024.

What is Hannah Valantine's role at CDNA?

Hannah Valantine serves as a Director on the Board of CareDx, Inc. (CDNA).